Blood and Marrow Transplantation & Cellular Therapy

World Class Expertise in Patient Care and Research

Message From the Chief

Welcome to the Blood and Marrow Transplantation & Cellular Therapy Division. We are a nationally recognized center of excellence, fully accredited by the Foundation for the Accreditation of Cellular Therapy (FACT) and a proud member of the Blood and Marrow Transplant Clinical Trials Network of the National Cancer Institute.

Listen to the latest podcast of The Bloodline with LLS

Stanford Medicine’s Lori Muffly, MD and Matthew Frank, MD, PhD from Stanford Medicine in Stanford, CA, were recently featured on The Bloodline with LLS, the podcast by The Leukemia & Lymphoma Society (LLS) for patients and caregivers. In this episode, the doctors delve into what Minimal/Measurable Disease (MRD) is, which blood cancers testing is currently used on, and how we can utilize it to more accurately monitor patients and customize treatment. The doctors also share exciting possibilities on how MRD and other testing can benefit patients in the future. 

Learn more about our highly innovative clinical trials for leukemia and MDS:

BMT 372. Phase 1 reduced intensity

BMT 377. Phase 3 full intensity

BMT 378. Phase 1 full intensity with CAR-T

About Us

The BMT-CT program at Stanford performs autologous and allogeneic transplantations for over 450 patients each year. The program has been very successful with a history of limited morbidity rates and acute mortality that is well below most published reports.

BMT Fellowship

Since 2007, the program has trained more than 45 physicians with majority of our graduates now working in the field of transplantation and cellular therapy throughout the country. 

Division Events

Recent stories

Make a Gift

Our cutting-edge research is developing novel immunotherapy for cancer. Support the BMT Division by making a donation to our research fund.


In this interview, Dr. Miklos talks in-depth about CAR T-cell therapy, mantle cell lymphoma treatments, allogeneic transplants, and gives his thoughts on future therapies.

Cellular immunotherapy is a new way of treating cancer. Cellular immunotherapy is a breakthrough because it's a living therapy; the cells that are administered can last in patients for weeks, months, even years. SCI members Crystal Mackall, MD and David Miklos, MD, PhD opened the first ever clinical trial for a bi-specific (CD19xCD22) CAR-T cell.


Over 400 patients received bone marrow or stem cell transplants at Stanford last year. 

Karl G. Blume, M.D. Memorial Lecture

The Karl G. Blume, MD Memorial Lectureship was established to honor Dr. Blume’s countless contributions to the field of blood and marrow transplantation, and to Stanford University and Stanford Hospital and Clinics. The lectureship is held the second Wednesday of each April at Stanford University’s Department of Medicine Grand Rounds. 

Dr. Blume and his team conducted Stanford’s first successful Bone Marrow Transplant on November 2, 1987. Today the program provides transplants to over 300 adult patients a year, with over 5,000 patients receiving transplants during the past 30 years.

Read the Tribute to Dr. Blume here.

Understanding Bone Marrow Transplantation - from the Clinical and Personal Perspectives